Comparing citrate and acetate dialysate for better hemodynamic stability during hemodialysis in ICU patients
Improved Hemodynamic Tolerance of Intermittent Hemodialysis Sessions in Intensive Care Unite (ICU) Using Citrate- vs Acetate-based Dialysate
This study is testing whether using citrate instead of acetate in dialysis can help ICU patients feel more stable and avoid low blood pressure during their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 48 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier de Bethune Research network |
| Locations | 5 sites (Béthune and 4 other locations) |
| Trial ID | NCT05936710 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the hemodynamic tolerance and effectiveness of citrate-based dialysate compared to acetate-based dialysate during intermittent hemodialysis in patients hospitalized in intensive care units. It focuses on patients experiencing intradialytic hypotension, a common complication that can lead to increased morbidity and mortality. By using citrate-based dialysate, the study seeks to determine if it can provide better stability and outcomes for patients undergoing hemodialysis. The study will involve patients who meet specific criteria related to acute renal failure and risk of hypotension.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are hospitalized in an intensive care unit with acute renal failure and at risk of per dialytic hypotension.
Not a fit: Patients with chronic renal insufficiency, unstable hemodynamic states, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved hemodynamic stability during hemodialysis, reducing complications and enhancing patient outcomes.
How similar studies have performed: While the use of citrate-based dialysate is a newer approach, previous studies have indicated potential benefits, but this specific comparison is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient ≥ 18 years old * Patient hospitalized in an intensive care unit * Patient with acute renal failure defined by a KDIGO stage ≥ 1 and suspected non-obstructive * Patient at risk of per dialytic hypotension (capillary refill time ≥ 3 seconds and/or cardiovascular SOFA ≥ 1 and/or lactatemia \> 2mmol/L) * Indication for Extra Renal Replacement Therapy with IHD. Exclusion Criteria: * Pregnant or breastfeeding woman * Known chronic renal insufficiency of any stage * Cardio-renal and hepato renal syndrome * Unstable hemodynamic state: refractory shock * Patient included in another interventional study likely to modify the hemodynamic state * Patient deprived of liberty * Patient under guardianship or curatorship * Patient not affiliated to a social security system
Where this trial is running
Béthune and 4 other locations
- Centre Hospitalier Béthune — Béthune, France (Recruiting)
- Chu — Caen, France (Recruiting)
- Centre Hospitalier Universitaire de Dijon — Dijon, France (Recruiting)
- CHRU Nancy — Nancy, France (Recruiting)
- CHU de ROUEN — Rouen, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Martin GÉRARD
- Email: mgerard@ch-bethune.fr
- Phone: 03.21.64.44.44
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.